**Claims**

Claim 1. An antigen-binding molecule which binds to a sarbecovirus spike protein from two or more different sarbecovirus wherein the antigen-binding molecule comprises:

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence GGFIGPHY

HC-CDR2 having the amino acid sequence IYISGST

HC-CDR3 having the amino acid sequence ARGGGYLETGPFEY

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence QSLLQNNGYNY

LC-CDR2 having the amino acid sequence LSS

LC-CDR3 having the amino acid sequence MQSLQIPGT.

Claim 2. The antigen binding molecule according to claim 1, wherein the antigen-binding molecule comprises a VH region having the amino acid sequence of SEQ ID NO:91 and a VL region having the amino acid sequence of SEQ ID NO:92.

Claim 3. The antigen-binding molecule according to claim 1 or claim 2, wherein the antigen-binding molecule binds to the receptor binding domain (RBD) of the Sarbecovirus spike protein.

Claim 4. The antigen-binding molecule according to any one of claims 1 to 3, wherein the antigen-binding molecule inhibits interaction between a sarbecovirus spike protein and Angiotensinogen converting enzyme 2 (ACE2).

Claim 5. The antigen-binding molecule according to any one of claims 1 to 4, wherein the antigen-binding molecule inhibits infection of ACE2-expressing cells by a sarbecovirus.

Claim 6. The antigen-binding molecule according to any one of claims 1 to 5, wherein the sarbecovirus is selected from the group comprising SARS-CoV-2, SARS-CoV-2 B.1.1.7, SARS-CoV-2 B.1.351, SARS-CoV-2 B.1.617.2, SARS-CoV-2 C37, SARS-CoV-2 B.1.621, SARS-CoV-2 P.1, SARS-CoV-2 BA.1, SARS-CoV-2 BA.2, SC2r-CoV BANAL-52,

SC2r-CoV BANAL-236, SC2r-CoV GD-1, SC2r-CoV RaTG13, SC2r-CoV GX-P5L, SC1r-CoV Rs2018B, SC1r-CoV RsSHC014, SC1r-CoV LYRa11, SC1r-CoV WIV-1, and SARS-CoV.

Claim 7. A nucleic acid, or a plurality of nucleic acids, optionally isolated, encoding the antigen-binding molecule according to any one of claims 1 to 6.

Claim 8. An expression vector, or a plurality of expression vectors, comprising a nucleic acid or a plurality of nucleic acids according to claim 7.

Claim 9. A cell comprising an antigen-binding molecule according to any one of claims 1 to 6, a nucleic acid or plurality of nucleic acids according to claim 7, or an expression vector or plurality of expression vectors according to claim 8.

Claim 10. A method for producing antigen-binding molecule which binds to a sarbecovirus spike protein, comprising culturing a cell comprising a nucleic acid or a plurality of nucleic acids according to claim 7, or an expression vector or plurality of expression vectors according to claim 8, under conditions suitable for expression of an antigen-binding molecule by the cell.

Claim 11. A composition comprising the antigen-binding molecule according to any one of claims 1 to 6, the nucleic acid or the plurality of nucleic acids according to claim 7, the expression vector or the plurality of expression vectors according to claim 8, or a cell according to claim 9, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

Claim 12. Use of the antigen-binding molecule according to any one of claims 1 to 6, a nucleic acid or a plurality of nucleic acids according to claim 7, an expression vector or a plurality of expression vectors according to claim 8, a cell according to claim 9, or a composition according to claim 11, in the manufacture of a medicament for use in treatment or prevention of a disease caused by infection with a sarbecovirus.

Claim 13. The use according to claim 12, wherein the sarbecovirus is selected from the group comprising SARS-CoV-2, SARS-CoV-2 B.1.1.7, SARS-CoV-2 B.1.351, SARS-CoV-2 B.1.617.2, SARS-CoV-2 C37, SARS-CoV-2 B.1.621, SARS-CoV-2 P.1, SARS-CoV-2 BA.1, SARS-CoV-2 BA.2, SC2r-CoV BANAL-52, SC2r-CoV BANAL-236, SC2r-CoV GD-1, SC2r-CoV RaTG13, SC2r-CoV GX-P5L, SC1r-CoV Rs2018B, SC1r-CoV RsSHC014, SC1r-CoV LYRa11, SC1r-CoV WIV-1, and SARS-CoV.